(Hypertension. 1999;33:1406-1413.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Mechanistic Differences of Various AT1-Receptor Blockers in Isolated Vessels of Different Origin
From the Department of Cardiovascular Pharmacology, Preclinical R&D, Astra Hässle AB, Mölndal, Sweden.
Correspondence to Peter Morsing, PhD, CV Pharmacology, Preclinical R&D, Astra Hässle AB, S 431 83 Mölndal, Sweden. E-mail peter.morsing{at}hassle.se.astra.com
Abstract—The functional inhibitory characteristics of the angiotensin II type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro. Moreover, plasma-protein binding was determined, and the binding was high (>98.5%) for all ARBs. These values were needed to relate the concentrations of the ARBs used in vitro to the nonprotein bound concentrations in clinical use. In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the angiotensin II (Ang II) concentration-response curve. Losartan, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to Ang II. The inhibitory effect of candesartan developed slowly (maximal effect after >30 minutes) and lasted >2 hours despite repeated washing of the vessels. The effect of losartan, irbesartan, and EXP had a faster onset, and most of the inhibitory effect disappeared after washing. The duration of the inhibitory effects of the ARBs were not related to lipophilicity of the compounds. Cooling of the rat portal vein preparations to 4°C before administration of candesartan prevented the persistent inhibition of Ang II response seen at 37°C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the Ang II response were independent of the incubation temperature before washing. In addition, when candesartan was given to conscious rats, the inhibitory effect on Ang II–induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours. It is concluded that functional inhibitory characteristics of candesartan differ from those of the other ARBs tested. At clinically relevant concentrations, candesartan is an insurmountable and long-lasting antagonist of the vascular contractile responses to Ang II.
Key Words: receptors, angiotensin • aorta • portal vein • protein binding • pharmacology
This article has been cited by other articles:
 |
|
 |
|
  K. M. Baker and R. Kumar Intracellular angiotensin II induces cell proliferation independent of AT1 receptor Am J Physiol Cell Physiol, November 1, 2006; 291(5): C995 - C1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Mitchell and J. J. Mullins Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1210 - F1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Morgan, A. Anderson, D. Bertram, and R. J. MacInnis Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria Journal of Renin-Angiotensin-Aldosterone System, June 1, 2004; 5(2): 64 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Kusaka, G. Kusaka, C. Zhou, M. Ishikawa, A. Nanda, D. N. Granger, J. H. Zhang, and J. Tang Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2442 - H2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sawathiparnich, L. J. Murphey, S. Kumar, D. E. Vaughan, and N. J. Brown Effect of Combined AT1 Receptor and Aldosterone Receptor Antagonism on Plasminogen Activator Inhibitor-1 J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3867 - 3873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The DIRECT Programme Study Group and N. Chaturvedi The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 255 - 261. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Pantev, E. Stenman, A. Wackenfors, L. Edvinsson, and M. Malmsjo Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries Eur J Heart Fail, December 1, 2002; 4(6): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Widdop, K. Matrougui, B. I. Levy, and D. Henrion AT2 Receptor-Mediated Relaxation Is Preserved After Long-Term AT1 Receptor Blockade Hypertension, October 1, 2002; 40(4): 516 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Maillard, C. Perregaux, C. Centeno, J. Stangier, W. Wienen, H.-R. Brunner, and M. Burnier In Vitro and in Vivo Characterization of the Activity of Telmisartan: An Insurmountable Angiotensin II Receptor Antagonist J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gohlke, S. Weiss, A. Jansen, W. Wienen, J. Stangier, W. Rascher, J. Culman, and T. Unger AT1 Receptor Antagonist Telmisartan Administered Peripherally Inhibits Central Responses to Angiotensin II in Conscious Rats J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 62 - 70. [Abstract] [Full Text]
|
|
|
|
|
|
G. Vauquelin, F. L. Fierens, I. Verheijen, and P. M. Vanderheyden Distinctions between non-peptide angiotensin II AT1-receptor antagonists Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S24 - S31. [Abstract] [PDF]
|
|
|
|
|
|
H. Ytterberg and L. Edvinsson Characterisation of angiotensin II receptors in isolated human subcutaneous resistance arteries Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S37 - S41. [Abstract] [PDF]
|
|
|
|
|
|
H. Ytterberg and L. Edvinsson Evidence for a cyclic AMP-dependent pathway in angiotensin AT1-receptor activation of human omental arteries Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S42 - S47. [Abstract] [PDF]
|
|
|
|
|
|
M. P Maillard, C. Centeno, A. Frostell-Karlsson, H. R Brunner, and M. Burnier Does protein binding modulate the effect of angiotensin II receptor antagonists? Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S54 - S58. [Abstract] [PDF]
|
|
|
|
|
|
E. Abro, C. D Griffiths, T. O Morgan, and L. M. Delbridge Regression of cardiac hypertrophy in the SHR by combined renin-angiotensin system blockade and dietary sodium restriction Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S148 - S153. [Abstract] [PDF]
|
|
|
|
|
|
W. F van Rodijnen, T. A van Lambalgen, M. E van Teijlingen, G.-J. Tangelder, and P. M ter Wee Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S204 - S210. [Abstract] [PDF]
|
|
|
|
|
|
M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]
|
|
|
|
|
|
F. L. Fierens, P. M. Vanderheyden, Z. Gaborik, T. Le Minh, J.-P. De Backer, L. Hunyady, A. Ijzerman, and G. Vauquelin Lys 199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 283 - 288. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Omoro, D. S. A. Majid, S. S. El Dahr, and L. G. Navar Roles of ANG II and bradykinin in the renal regional blood flow responses to ACE inhibition in sodium-depleted dogs Am J Physiol Renal Physiol, August 1, 2000; 279(2): F289 - F293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Vanderheyden, I. Verheijen, F. L. Fierens, J.-P. De Backer, and G. Vauquelin Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 159 - 165. [Abstract] [PDF]
|
|
|
|
|
|
K. Inoue, H. Nishimura, J. Kubota, and Y. Kitaura Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 180 - 183. [Abstract] [PDF]
|
|
|
|
|
|
N. K Hollenberg and P. S Sever The past, present and future of hypertension management: a potential role for AT1-receptor antagonists Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 5 - 10. [Abstract] [PDF]
|
|